Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Eclinicalmedicine|July 16, 2024
Projecting the clinical burden of chronic kidney disease at the patient level (<i>Inside CKD</i>): a microsimulation modelling studyGlenn M Chertow, Ricardo Correa-Rotter, Kai-Uwe Eckardt, et al.
The Lancet. Diabetes & Endocrinology|December 22, 2019
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort studyHiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, et al.
The Lancet. Diabetes & Endocrinology|June 20, 2020
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Carolyn S P Lam, Dae Jung Kim, et al.
Cardiovascular Diabetology|August 1, 2021
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL dataKamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, et al.
Cardiovascular Diabetology|August 31, 2023
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and AsiaDorte Vistisen, Bendix Carstensen, Patorno Elisabetta, et al.
Diabetes & Metabolism|January 7, 2023
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) studyAvraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, et al.
Pageof 7